Cipla Ltd. did not share a great deal of detail on the much publicized licensing pact with Gilead Sciences Inc. for remdesivir at the firm’s fourth-quarter 2020 earnings call but the management drew attention to the momentum in the respiratory segment, where the firm has now filed an ANDA for a generic version of GlaxoSmithKline PLC’s Advair Diskus (salmeterol/fluticasone) in the US.
Cipla, which aspires for lung leadership across markets, also highlighted the unlocking of its respiratory franchise in the US with...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
